- US Recovery to be Weak, Erratic: Top Fed Officials
- Retail Earnings in Focus Ahead of Shopping Season
- Apple Surpasses Nokia as Top Handset Maker by Profit
- Brazil's Largest Cities Hit by Blackout
- In This Relay-Race Market, Who Gets Baton Next?
- Workers Staying Put at Their Jobs as Jobless Surges
- Ponzi Proceeds: Bidding on Madoff's Toys
- Toll Brothers: More Contracts Signed, but Sales Down
- Bear Stearn Fund Managers Not Guilty on All Counts
- Beware of 'Trampling Effect' When Market Tops: Manager
- Gold Heading to $1150: Art Hogan
- Starbucks Brews Up Growth
- Farr: An Extended Period—No Fat Lady in Sight
- More Upside if S&P Passes This Number: Market Pro
- Murdoch Lashes Out At Google
- Fighting The Flu Vaccine Critics
- Nov. 10: Unusual Volume Leaders
- Shadow Inventory Dwarfs Loan Mods
MOST SHARED
- Apple Surpasses Nokia as Top Cellphone Maker by Profits
- Herbalife Vs. Hedge Funds
- China Factory Output Leaps to 19-Month Highs
- America Is On Sale
- Three Things the US Can Do To Stop the Dollar's Decline
- Toll Brothers: More Contracts Signed, but Sales Down
- Cramer Jeers J&J, Applauds Abbott
- Gold Heading to $1150: Art Hogan
- SingTel Posts Higher Quarterly Profit, Cautious on Growth
Text Size 
A new study shows lowering cholesterol could increase the risk of cancer.
The Journal of the American College of Cardiology reports that researchers observed as much as triple the incidence of cancer among patients who lowered their bad or LDL cholesterol using the popular drugs known as statins. The rate, the study says, was especially high among patients with cholesterol levels below 160.
But they don't know if the cancer was caused by the drug, the low cholesterol or happenstance. The doctors who did the study say the heart benefits of statins still outweigh the risk of cancer and that patients should not stop taking their medication.
Researchers looked at the results of clinical trials involving more than 75,000 people who took statins. They're the
biggest segment of the drug industry accounting for $18 billion in sales in 2006, according to Verispan, which monitors prescriptions.
Pfizer's [PFE
Loading...
()
] Lipitor, Merck [MRK
Loading...
()
] and Schering-Plough's [SGP
Loading...
()
] Vytorin and AstraZeneca's [AZN
Loading...
()
] Crestor are among the top-selling brand-name statins.
The editor of JACC says the staff debated for three weeks whether to publish this study, but in the end decided that "these findings could not be ignored, that they did warrant further investigation, and that they should be aired in public."
Pfizer, which makes the world's top-selling statin, Lipitor, called the JACC study limited. The company said similar, larger analyses have shown no increased risk of cancer on the drug and that a company-sponsored clinical trial of 10,000 patients also showed no increased risk of cancer death.
Pfizer also said that the JACC study indicates no causal relationship between statins and cancer.
Print
Email
- Vote and suggest your own, and remember--there's a fine line between a hero and a zero.
- If you are lucky enough to have money and the time, this is a great time to see America, says CNBC's Jane Wells.
- What’s powering your microwave, fridge and computer? Part of it is fuel from Russian nuclear weapons. The NYT reports.
- One author sees lessons for you in Disney’s recent Makeover of Mickey Mouse: “Nice” doesn’t always win.
- With 123 years of history, slogans and commercials, Coca-Cola is the most recognized brand on earth.
- The opening of a virtual pet store in “World of Warcraft” could prove a cash bonanza for Activision-Blizzard.
Data is a real-time snapshot *Data is delayed at least 15 minutes